Dr. Vince O’Neill, Chief Medical Officer of BioXcel Therapeutics, says company potentially breaking new ground in cancer treatment.

BRANFORD: BioXcel Therapeutics (“BTI”), a research stage [founded in 2005], announced a research collaboration with San Francisco based the publicly traded Nektar Therapeutics [Nasdaq: NKTR] with a $6 billion market cap, research/development stage bio-tech.

The companies will “explore the novel combination of Nektar’s NKTR-214, a CD122-biased agonist, and BTI’s BXCL701, a small molecule immune-modulator and DPP 8/9 and FAP inhibitor, for the treatment of multiple oncology indications.”

According to the companies, the goal of this collaboration is to leverage “the complementary mechanisms of NKTR-214 and BXCL701 to boost the body’s own immune system and overcome local immunosuppressive mechanisms in the tumor microenvironment. The collaborative research studies will evaluate the potential of the therapies in preclinical mouse models of pancreatic and prostate cancer.”

Dr. Vince O’Neill, Chief Medical Officer of BioXcel Therapeutics, said ‘the combination immunotherapy represents a potentially groundbreaking innovation in cancer treatment. Adding, “the complementary mechanisms of BXCL701 and NKTR-214 may stimulate both innate and acquired immune responses while inhibiting the immuno-suppressive effect of the tumor microenvironment, representing a significant potential opportunity to develop a novel therapy to fight cancer.”

BioXcel says it “utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology.” Adding, “the company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.”